A “failure to communicate” claim against the maker of generic Reglan was completely preempted by federal law regulating the pharmaceutical industry, the 11th U.S. Circuit Court of Appeals has ruled in affirming judgment.Read More »
Federal law does not preempt a product liability suit against drug maker PLIVA based on the company’s alleged failure to update its warning label for the generic form of Reglan, the 6th U.S. Circuit Court of Appeals has ruled in ...Read More »
State law allows the user of a generic drug to sue the maker of the name-brand drug for fraudulent misrepresentation, the Alabama Supreme Court has ruled in answering a certified question from a U.S. District Court.Read More »
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
Tagged with: Accutane adverse events Avandia Bayer Chantix Coumadin drug litigation FDA Food and Drug Administration GlaxoSmithKline Hoffman-LaRoche Institute for Safe Medication Practices Johnson & Johnson Levaquin Pfizer Pradaxa prescription drugs Reglan Wyeth Yasmin YazRead More »
Reglan lawsuits are rising; so is debate over preemption for failure-to-warn claims against makers of generic versions of the drug. The FDA and Solicitor General have been asked for opinions on generic preemption.Read More »